Early liver biopsy, intraparenchymal cholestasis, and prognosis in patients with alcoholic steatohepatitis

BMC Gastroenterology

Volumn 11, Issue , 2011, Pages

  Spahr, Laurent ^a   Rubbia Brandt, Laura ^a   Genevay, Muriel ^a   Hadengue, Antoine ^a   Giostra, Emiliano ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; PREDNISONE;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ALCOHOLIC FATTY LIVER; ARTICLE; BILIRUBIN BLOOD LEVEL; CHOLESTASIS; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; INTRAPARENCHYMAL CHOLESTASIS; LIVER BIOPSY; LIVER CELL DAMAGE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL CHEMOTAXIS; OUTCOME ASSESSMENT; PROGNOSIS; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SURVIVAL RATE; ALCOHOL LIVER CIRRHOSIS; BLOOD; COHORT ANALYSIS; FOLLOW UP; HOSPITALIZATION; INTRAHEPATIC CHOLESTASIS; KAPLAN MEIER METHOD; LIVER; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEEDLE BIOPSY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL;

ADULT; AGE FACTORS; AGED; BILIRUBIN; BIOPSY, FINE-NEEDLE; CHOLESTASIS, INTRAHEPATIC; COHORT STUDIES; FATTY LIVER, ALCOHOLIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER; LIVER CIRRHOSIS, ALCOHOLIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 80055020944     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-11-115     Document Type: Article

References (40)

1. Spahr L, Hadengue A. Alcoholic liver disease: natural history, diagnosis, clinical features, evaluation, prognosis and management. Textbook of Hepatology: from Basic Science to Clinical Practice 2007, 2:1157-1178. Oxford: Blackwell Publishing, Rodes J, Benhamou JP, Blei A, Reichen J, Rizzetto M.
2. Mathurin P, Mendenhall CL, Carithers RL, Ramond MJ, Maddrey WC, Garstide P, Rueff B, Naveau S, Chaput JC, Poynard T. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002, 36(4):480-487. 10.1016/S0168-8278(01)00289-6, 11943418.
3. Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, de Silva HJ, Hamid SS, Jalan R, Komolmit P, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 2009, 3(1):269-282. 10.1007/s12072-008-9106-x, 2712314, 19669378.
4. Srikureja W, Kyulo NL, Runyon BA, Hu KQ. MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. J Hepatol 2005, 42(5):700-706. 10.1016/j.jhep.2004.12.022, 15826720.
5. Alcoholic liver disease: morphological manifestations. Review by an international group. Lancet 1981, 1(8222):707-711.
6. Katoonizadeh A, Laleman W, Verslype C, Wilmer A, Maleux G, Roskams T, Nevens F. Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. Gut
7. Elphick DA, Dube AK, McFarlane E, Jones J, Gleeson D. Spectrum of liver histology in presumed decompensated alcoholic liver disease. Am J Gastroenterol 2007, 102(4):780-788. 10.1111/j.1572-0241.2006.01034.x, 17222323.
8. Eng SC, Taylor SL, Reyes V, Raaka S, Berger J, Kowdley KV. Hepatic iron overload in alcoholic end-stage liver disease is associated with iron deposition in other organs in the absence of HFE-1 hemochromatosis. Liver Int 2005, 25(3):513-517. 10.1111/j.1478-3231.2005.01004.x, 15910487.
9. Nissenbaum M, Chedid A, Mendenhall C, Gartside P. Prognostic significance of cholestatic alcoholic hepatitis. VA Cooperative Study Group #119. Dig Dis Sci 1990, 35(7):891-896. 10.1007/BF01536804, 2364844.
10. Spahr L, Garcia I, Bresson-Hadni S, Rubbia-Brandt L, Guler R, Olleros M, Chvatchko Y, Hadengue A. Circulating concentrations of interleukin-18, interleukin-18 binding protein, and gamma interferon in patients with alcoholic hepatitis. Liver Int 2004, 24(6):582-587. 10.1111/j.1478-3231.2004.0967.x, 15566508.
11. Spahr L, Giostra E, Frossard JL, Bresson-Hadni S, Rubbia-Brandt L, Hadengue A. Soluble TNF-R1, but not tumor necrosis factor alpha, predicts the 3-month mortality in patients with alcoholic hepatitis. J Hepatol 2004, 41(2):229-234. 10.1016/j.jhep.2004.04.028, 15288471.
12. Spahr L, Rubbia-Brandt L, Frossard JL, Giostra E, Rougemont AL, Pugin J, Fischer M, Egger H, Hadengue A. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol 2002, 37(4):448-455. 10.1016/S0168-8278(02)00230-1, 12217597.
13. Chand N, Sanyal AJ. Sepsis-induced cholestasis. Hepatology 2007, 45(1):230-241. 10.1002/hep.21480, 17187426.
14. Louvet A, Wartel F, Castel H, Dharancy S, Hollebecque A, Canva-Delcambre V, Deltenre P, Mathurin P. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology 2009, 137(2):541-548. 10.1053/j.gastro.2009.04.062, 19445945.
15. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. Journal of hepatology 2010, 53(3):397-417.
16. O'Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Hepatology 2009, 51(1):307-328.
17. Mathurin P, Duchatelle V, Ramond MJ, Degott C, Bedossa P, Erlinger S, Benhamou JP, Chaput JC, Rueff B, Poynard T. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology 1996, 110(6):1847-1853. 10.1053/gast.1996.v110.pm8964410, 8964410.
18. Spahr L, Rubbia-Brandt L, Pugin J, Giostra E, Frossard JL, Borisch B, Hadengue A. Rapid changes in alcoholic hepatitis histology under steroids: correlation with soluble intercellular adhesion molecule-1 in hepatic venous blood. J Hepatol 2001, 35(5):582-589. 10.1016/S0168-8278(01)00190-8, 11690703.
19. Kalambokis G, Manousou P, Vibhakorn S, Marelli L, Cholongitas E, Senzolo M, Patch D, Burroughs AK. Transjugular liver biopsy--indications, adequacy, quality of specimens, and complications--a systematic review. J Hepatol 2007, 47(2):284-294. 10.1016/j.jhep.2007.05.001, 17561303.
20. Zafrani E. Pathology of alcoholic liver disease. Textbook of Hepatology; From basic Science to Clinical Practice 2007, 2:1148-1156. Oxford: Blackwell Publishing 2007, Rodes J, Benhamou JP, Blei A, Reichen J, Rizzetto M.
21. Perrillo RP, Griffin R, DeSchryver-Kecskemeti K, Lander JJ, Zuckerman GR. Alcoholic liver disease presenting with marked elevation of serum alkaline phosphatase. A combined clinical and pathological study. Am J Dig Dis 1978, 23(12):1061-1066. 10.1007/BF01072879, 736013.
22. Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, Dharancy S, Texier F, Hollebecque A, Serfaty L, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007, 45(6):1348-1354. 10.1002/hep.21607, 17518367.
23. McGill DB. Steatosis, cholestasis, and alkaline phosphatase in alcoholic liver disease. Am J Dig Dis 1978, 23(12):1057-1060. 10.1007/BF01072878, 736012.
24. Jones A, Selby PJ, Viner C, Hobbs S, Gore ME, McElwain TJ. Tumour necrosis factor, cholestatic jaundice, and chronic liver disease. Gut 1990, 31(8):938-939. 10.1136/gut.31.8.938, 1378628, 2387521.
25. Layden TJ, Boyer JL. Taurolithocholate-induced cholestasis: taurocholate but not dehydrocholate, reverses cholestasis and bile canalicular membrane injury. Gastroenterology 1977, 73(1):120-128.
26. Trinchet JC, Gerhardt MF, Balkau B, Munz C, Poupon RE. Serum bile acids and cholestasis in alcoholic hepatitis. Relationship with usual liver tests and histological features. J Hepatol 1994, 21(2):235-240. 10.1016/S0168-8278(05)80401-5, 7989715.
27. Pelletier G, Roulot D, Davion T, Masliah C, Causse X, Oberti F, Raabe JJ, Van Lemmens C, Labadie H, Serfaty L. A randomized controlled trial of ursodeoxycholic acid in patients with alcohol-induced cirrhosis and jaundice. Hepatology 2003, 37(4):887-892. 10.1053/jhep.2003.50118, 12668982.
28. Wong F, Bernardi M, Balk R, Christman B, Moreau R, Garcia-Tsao G, Patch D, Soriano G, Hoefs J, Navasa M. Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut 2005, 54(5):718-725. 10.1136/gut.2004.038679, 1774473, 15831923.
29. Geier A, Dietrich CG, Voigt S, Kim SK, Gerloff T, Kullak-Ublick GA, Lorenzen J, Matern S, Gartung C. Effects of proinflammatory cytokines on rat organic anion transporters during toxic liver injury and cholestasis. Hepatology 2003, 38(2):345-354. 10.1053/jhep.2003.50317, 12883478.
30. Tung BY, Carithers RL. Cholestasis and alcoholic liver disease. Clin Liver Dis 1999, 3(3):585-601. 10.1016/S1089-3261(05)70086-6, 11291240.
31. Giraud V, Naveau S, Balian A, Belda E, Capron F, Lemaigre G, Chaput JC. [Predictive risk factors for progression to cirrhosis in early stage alcoholic liver disease]. Gastroenterol Clin Biol 1998, 22(12):997-1002.
32. Katoonizadeh A, Laleman W, Verslype C, Wilmer A, Maleux G, Roskams T, Nevens F. Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. Gut 2010, 59(11):1561-1569. 10.1136/gut.2009.189639, 20675694.
33. Raynard B, Balian A, Fallik D, Capron F, Bedossa P, Chaput JC, Naveau S. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002, 35(3):635-638. 10.1053/jhep.2002.31782, 11870378.
34. Ganne-Carrie N, Christidis C, Chastang C, Ziol M, Chapel F, Imbert-Bismut F, Trinchet JC, Guettier C, Beaugrand M. Liver iron is predictive of death in alcoholic cirrhosis: a multivariate study of 229 consecutive patients with alcoholic and/or hepatitis C virus cirrhosis: a prospective follow up study. Gut 2000, 46(2):277-282. 10.1136/gut.46.2.277, 1727829, 10644325.
35. Yokoyama Y, Nagino M, Nimura Y. Mechanism of impaired hepatic regeneration in cholestatic liver. J Hepatobiliary Pancreat Surg 2007, 14(2):159-166. 10.1007/s00534-006-1125-1, 17384907.
36. Cardin R, D'Errico A, Fiorentino M, Cecchetto A, Naccarato R, Farinati F. Hepatocyte proliferation and apoptosis in relation to oxidative damage in alcohol-related liver disease. Alcohol Alcohol 2002, 37(1):43-48.
37. Katoonizadeh A, Nevens F, Verslype C, Pirenne J, Roskams T. Liver regeneration in acute severe liver impairment: a clinicopathological correlation study. Liver Int 2006, 26(10):1225-1233. 10.1111/j.1478-3231.2006.01377.x, 17105588.
38. Mathurin P, O'Grady J, Carithers RL, Phillips M, Louvet A, Mendenhall CL, Ramond MJ, Naveau S, Maddrey WC, Morgan TR. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011, 60(2):255-260. 10.1136/gut.2010.224097, 20940288.
39. Forrest EH, Evans CD, Stewart S, Phillips M, Oo YH, McAvoy NC, Fisher NC, Singhal S, Brind A, Haydon G, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005, 54(8):1174-1179. 10.1136/gut.2004.050781, 1774903, 16009691.
40. Elphick DA, Dube AK, McFarlane E, Jones J, Gleeson D. Spectrum of liver histology in presumed decompensated alcoholic liver disease. Am J Gastroenterol 2007, 102(4):780-788. 10.1111/j.1572-0241.2006.01034.x, 17222323.